Equities researchers at Piper Sandler began coverage on shares of Harmony Biosciences (NASDAQ:HRMY) in a research note issued to investors on Monday, MarketBeat reports. The brokerage set an “overweight” rating and a $61.00 price target on the stock. Piper Sandler’s price target suggests a potential upside of 71.35% from the company’s current price.
Separately, Goldman Sachs Group initiated coverage on shares of Harmony Biosciences in a research report on Sunday. They set a “neutral” rating and a $43.00 price target for the company.
Shares of NASDAQ:HRMY opened at $35.60 on Monday. Harmony Biosciences has a 52-week low of $31.88 and a 52-week high of $47.37.
About Harmony Biosciences
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients living with rare neurological disorders. Its lead product includes WAKIX (pitolisant) for the treatment of pediatric patients suffering from narcolepsy. Harmony Biosciences Holdings, Inc was formerly known as Harmony Biosciences II, Inc and changed its name to Harmony Biosciences Holdings, Inc in February 2020.
Featured Article: Why do company’s buyback their stock?
Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.